Russian national consensus. Diagnostics and treatment of hypopituitarism in children and adolescences

The materials of the National Consensus reflect the modern domestic and international experience on this issue. Before conducting a specialized endocrinological examination of a short child, all other causes of short stature should be excluded: severe somatic diseases in a state of decompensation that can affect growth velocity, congenital systemic skeletal diseases, syndromic short stature (all girls with growth retardation require a mandatory study of karyotype, depending on the presence or absence of phenotypic signs of Turner syndrome), endocrine diseases in decompensation. A specialized examination of the state of GH-IGF-I axis is carried out when the proportionally folded child has pronounced short stature: if the child's height is < –2.0 SDS, if the difference between the child's height SDS and child's midparental height SDS exceeds 1.5 SDS and/or a low growth velocity. The consensus reflects clear criteria for the diagnosis of GH-deficiency, central hypothyroidism, central hypocorticosolism, central hypogonadism, diabetes insipidus, hypoprolactinemia, and also the criteria for their compensation. The dose of somatropin with GH-deficiency in children and adolescents is 0.025–0.033 mg/kg/day. With total somatotropic insufficiency, especially in young children, it is advisable to start therapy with somatropin from lower doses: 25–50% of the substitution, gradually increasing it within 3–6 months to optimal. In children with a growth deficit when entering puberty, the dose may be increased to 0.045–0.05 mg/kg/day. With the development of side effects, the dose of somatropin can be reduced (by 30–50%), or temporarily canceled (depending on the severity of the clinical picture) until the complete disappearance of undesirable symptoms. With swelling of the optic nerve, treatment is temporarily stopped until the picture of the fundus of the eye fully normalizes. If therapy has been temporarily discontinued, treatment is resumed in smaller doses (50% of the initial) with a gradual (within 1–3 months) return to the optimum. GH treatment at pediatric doses not continue beyond attainment of a growth velocity below 2–2.5 cm/year, closure of the epiphy-seal growth zones, or earlier, when: the achievement of genetically predicted height, but not more than 170 cm in girls, 180 cm in boys, the patient's desire and his parents / legal representatives satisfied with the achieved result of the final height. Re-evaluation of the somatotropic axis is carried out after reaching the adult height, after 1–3 months GH therapy will be discontinued. Patients with isolated GH-deficiency or patients with 1 (besides GH) pituitary hormone deficiencies in the presence of a normal IGF-1 level (against the background of somatropin withdrawal) and not having molecular genetic confirmation of the diagnosis need re- evaluation. Patients with two or more (besides GH) pituitary hormone deficiencies, acquired hypothalamic-pituitary lesions due to operations on the pituitary and irradiation of the hypothalamic-pituitary area (if the IGF-1 level is low against somatropin withdrawal), specific pituitary/ hypothalamic structural defect on MRI, gene defects of the GH-IGF-I system do not need re- evaluation. If GH deficiency is confirmed, treatment with somatropin is resumed at metabolic doses of 0.01—0.003 mg/kg/day under the control of the IGF-I level in the blood (measurement 1 time in 6 months), the indicator should not exceed the upper limit of the reference value for the corresponding age and floor. © 2018 by the MediaSphere.

Nagaeva E.V.1 , Shiryaeva T.Y.1 , Peterkova V.A.1 , Bezlepkina O.B.1 , Tiulpakov A.N.1 , Strebkova N.А.1 , Kiyaev A.V.2 , Petryaykina E.E. 3 , Bashnina E.B.4 , Malievsky O.А.5 , Taranushenko T.E.6 , KOstrova I.B.7 , Shapkina L.А.8 , Dedov I.I.1, 9
Номер выпуска
  • 1 Endocrinology Research Centre, 11 Dm. Ulyanova street, Moscow, 117036, Russian Federation
  • 2 Urals State Medical University, Ekaterinburg, Russian Federation
  • 3 RUDN University Medical Institute, Moscow, Russian Federation
  • 4 North-Western State Medical University named after I.I Mechnikov, Saint Petersburg, Russian Federation
  • 5 Bashkortostan State Medical University, Ufa, Russian Federation
  • 6 Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation
  • 7 Children Republic Ckinical Hospital named after N.M. Kuraev, Makhachkala, Russian Federation
  • 8 Pacific State Medical University, Vladivostok, Russian Federation
  • 9 I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Ключевые слова
Central hypocortisolism; Central hypogonadism; Central hypothyroidism; Consensus; Growth hormone; Growth hormone deficiency; Hypopituitarism; Somatropin
Дата создания
Дата изменения
Постоянная ссылка

Другие записи